



Phosphagenics Participation in 'New Innovations in Drug Delivery Technology' Webcast

12 April 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce the Company's recent inclusion as part of the Nature.com webcast 'New innovations in drug delivery technology', hosted and sponsored by BioPharma Dealmakers.

Conducted as a live roundtable discussion between prominent industry leaders, the webcast explored recent advances in drug delivery and enhancement technologies across the industry, including Phosphagenics' TPM[®] drug delivery technology. Concluding the roundtable discussion, participants were invited to engage in a Q&A session with the speakers.

Phosphagenics Limited was represented by Dr Paul Gavin, a 15-year veteran of the company and current Chief Scientific Officer. Dr Gavin is also an inventor of Phosphagenics' propriety TPM[®] drug delivery technology and an expert in the application of this technology in the management of chronic pain.

Dr Gavin said "This was a great opportunity for Phosphagenics to showcase its drug delivery technology, in a global and highly respected forum, and is an important part of our business development program. I'd like to thank Nature.com and BioPharma for including Phosphagenics and myself in such a thought-provoking forum".

Other webcast participants included:

- **Dr Patrick Anquetil**, Chief Executive Officer of Portal Instruments Inc.
- **Dr Joseph Sarret**, Chief Business Officer of Corium International
- **Dr Kevin Nelson**, Founder & Chief Scientific Officer of TissueGen Inc.
- **Dr Roy Farfara**, Chief Scientific Officer of TrioxNano
- **Moderator: Raveena Bhambra**, Editor of *BioPharma Dealmakers*. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.

For the recording of the webcast – click [here](#).

Enquiries

Kyahn Williamson
WE Buchan
+61 3 9866 4722 / +61 401 018 828
Email: kwilliamson@buchanwe.com.au

About Phosphagenics

Phosphagenics Limited is focused on developing and commercialising innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM[®] (Targeted Penetration Matrix). TPM[®] is derived from Vitamin E using a unique, proprietary and patented process and has been proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Amongst its major projects, Phosphagenics' is developing TPM[®] enhanced patches, gels and injectable products for the human health market and is also developing TPM[®] to enhance the feed efficiency and health of livestock.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com